Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 328

1.

Risk Factors for Poor Pain Control after Opioid Switching from Oxycodone Tablet to Fentanyl Patch.

Morikawa N, Kasahara Y, Takahashi Y, Nishikura K, Nishihara M.

Biol Pharm Bull. 2019;42(10):1674-1678. doi: 10.1248/bpb.b19-00271.

2.

Clinical pharmacokinetics of oral azithromycin in epididymal tissue.

Sadahira T, Wada K, Ikawa K, Morikawa N, Mitsui M, Araki M, Fujiyoshi M, Ishii A, Watanabe M, Watanabe T, Nasu Y.

J Infect Chemother. 2019 Oct;25(10):832-834. doi: 10.1016/j.jiac.2019.05.011. Epub 2019 Jun 27.

PMID:
31255523
3.

Habitual coffee intake reduces all-cause mortality by decreasing heart rate.

Nohara-Shitama Y, Adachi H, Enomoto M, Fukami A, Nakamura S, Kono S, Morikawa N, Sakaue A, Hamamura H, Toyomasu K, Fukumoto Y.

Heart Vessels. 2019 Nov;34(11):1823-1829. doi: 10.1007/s00380-019-01422-0. Epub 2019 May 6.

PMID:
31062117
4.

Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.

Sen T, Rodriguez BL, Chen L, Corte CMD, Morikawa N, Fujimoto J, Cristea S, Nguyen T, Diao L, Li L, Fan Y, Yang Y, Wang J, Glisson BS, Wistuba II, Sage J, Heymach JV, Gibbons DL, Byers LA.

Cancer Discov. 2019 May;9(5):646-661. doi: 10.1158/2159-8290.CD-18-1020. Epub 2019 Feb 18.

PMID:
30777870
5.

Thrombospondin-2 as a Potential Risk Factor in a General Population.

Morikawa N, Adachi H, Enomoto M, Fukami A, Kumagai E, Nakamura S, Nohara Y, Nakao E, Kono S, Tsuru T, Sakaue A, Hamamura H, Fukumoto Y.

Int Heart J. 2019 Mar 20;60(2):310-317. doi: 10.1536/ihj.18-246. Epub 2019 Feb 8.

6.

The Use of Bromocriptine for Peripartum Cardiomyopathy after Twin Delivery via Oocyte Donation.

Morikawa N, Nakayoshi T, Yoshimura H, Watanabe M, Kumanomido J, Furusho A, Fukui D, Eto K, Nishida N, Nishihara M, A Kamiya C, Fukumoto Y.

Intern Med. 2019 Feb 15;58(4):541-544. doi: 10.2169/internalmedicine.1537-18. Epub 2018 Dec 18.

7.

LY341495, an mGluR2/3 Antagonist, Regulates the Immunosuppressive Function of Myeloid-Derived Suppressor Cells and Inhibits Melanoma Tumor Growth.

Morikawa N, Tachibana M, Ago Y, Goda H, Sakurai F, Mizuguchi H.

Biol Pharm Bull. 2018;41(12):1866-1869. doi: 10.1248/bpb.b18-00055.

8.

Risk factors increasing blood pressure in Japanese colorectal cancer patients treated with bevacizumab.

Nishihara M, Morikawa N, Yokoyama S, Nishikura K, Yasuhara M, Matsuo H.

Pharmazie. 2018 Nov 1;73(11):671-675. doi: 10.1691/ph.2018.8664.

PMID:
30396388
9.

Association between physical activity, occupational sitting time and mortality in a general population: An 18-year prospective survey in Tanushimaru, Japan.

Sakaue A, Adachi H, Enomoto M, Fukami A, Kumagai E, Nakamura S, Nohara Y, Kono S, Nakao E, Morikawa N, Tsuru T, Hamamura H, Yoshida N, Fukumoto Y.

Eur J Prev Cardiol. 2018 Nov 5:2047487318810020. doi: 10.1177/2047487318810020. [Epub ahead of print]

PMID:
30396293
10.

A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101).

Takashina T, Asahina H, Oizumi S, Yamada N, Harada M, Takamura K, Yokouchi H, Harada T, Honjo O, Ogi T, Morikawa N, Kinoshita I, Honda R, Nakano K, Kanazawa K, Amano T, Dosaka-Akita H, Isobe H, Nishimura M; Hokkaido Lung Cancer Clinical Study Group.

Int J Clin Oncol. 2018 Dec;23(6):1060-1069. doi: 10.1007/s10147-018-1318-z. Epub 2018 Jul 19.

11.

Data-Adaptive Spatiotemporal ERP Cleaning for Single-Trial BCI Implementation.

Molla MKI, Morikawa N, Islam MR, Tanaka T.

IEEE Trans Neural Syst Rehabil Eng. 2018 Jul;26(7):1334-1344. doi: 10.1109/TNSRE.2018.2844109. Epub 2018 Jun 4.

PMID:
29993552
12.

Cryoanalgesia in Patients Undergoing Nuss Repair of Pectus Excavatum: Technique Modification and Early Results.

Morikawa N, Laferriere N, Koo S, Johnson S, Woo R, Puapong D.

J Laparoendosc Adv Surg Tech A. 2018 Sep;28(9):1148-1151. doi: 10.1089/lap.2017.0665. Epub 2018 Apr 19.

PMID:
29672193
13.

Complex sparse spatial filter for decoding mixed frequency and phase coded steady-state visually evoked potentials.

Morikawa N, Tanaka T, Islam MR.

J Neurosci Methods. 2018 Jul 1;304:1-10. doi: 10.1016/j.jneumeth.2018.04.001. Epub 2018 Apr 11.

PMID:
29653130
14.

Antiproteinuric effects of renin-angiotensin inhibitors in lung cancer patients receiving bevacizumab.

Nihei S, Sato J, Harada T, Kuyama S, Suzuki T, Waga N, Saito Y, Kisara S, Yokota A, Okada K, Tsuchiya M, Terui K, Tadokoro Y, Chiba T, Kudo K, Oizumi S, Inoue A, Morikawa N.

Cancer Chemother Pharmacol. 2018 Jun;81(6):1051-1059. doi: 10.1007/s00280-018-3580-1. Epub 2018 Apr 12.

PMID:
29651572
15.

Population pharmacokinetics/pharmacodynamics of linezolid in sepsis patients with and without continuous renal replacement therapy.

Ide T, Takesue Y, Ikawa K, Morikawa N, Ueda T, Takahashi Y, Nakajima K, Takeda K, Nishi S.

Int J Antimicrob Agents. 2018 May;51(5):745-751. doi: 10.1016/j.ijantimicag.2018.01.021. Epub 2018 Feb 6.

PMID:
29425834
16.

Rikkunshito for Preventing Chemotherapy-Induced Nausea and Vomiting in Lung Cancer Patients: Results from 2 Prospective, Randomized Phase 2 Trials.

Harada T, Amano T, Ikari T, Takamura K, Ogi T, Fujikane T, Fujita Y, Taima K, Tanaka H, Sasaki T, Okumura S, Sugawara S, Yokouchi H, Yamada N, Morikawa N, Dosaka-Akita H, Isobe H, Nishimura M.

Front Pharmacol. 2018 Jan 16;8:972. doi: 10.3389/fphar.2017.00972. eCollection 2017.

17.

Twenty-four-Hour Urinary Potassium Excretion, But Not Sodium Excretion, Is Associated With All-Cause Mortality in a General Population.

Nohara-Shitama Y, Adachi H, Enomoto M, Fukami A, Kumagai E, Nakamura S, Kono S, Morikawa N, Nakao E, Sakaue A, Tsuru T, Fukumoto Y.

J Am Heart Assoc. 2018 Jan 4;7(1). pii: e007369. doi: 10.1161/JAHA.117.007369.

18.

Factors Influencing the Appearance of Oxaliplatin-Induced Allergy.

Nishihara M, Nishikura K, Morikawa N, Yokoyama S.

Biol Pharm Bull. 2017;40(12):2105-2109. doi: 10.1248/bpb.b17-00400.

19.

Clinical pharmacokinetics and pharmacodynamic target attainment of pazufloxacin in prostate tissue: Dosing considerations for prostatitis.

Nakamura K, Ikawa K, Nishikawa G, Kobayashi I, Narushima M, Muramatsu H, Morinaga S, Kajikawa K, Kato Y, Watanabe M, Zennami K, Kanao K, Morikawa N, Sumitomo M.

J Infect Chemother. 2017 Dec;23(12):809-813. doi: 10.1016/j.jiac.2017.08.005. Epub 2017 Oct 12.

PMID:
28923301
20.

Impact of cystatin C and microalbuminuria on cognitive impairment in the population of community-dwelling Japanese.

Kono S, Adachi H, Enomoto M, Fukami A, Kumagai E, Nakamura S, Nohara Y, Morikawa N, Nakao E, Sakaue A, Tsuru T, Fukumoto Y.

Atherosclerosis. 2017 Oct;265:71-77. doi: 10.1016/j.atherosclerosis.2017.08.022. Epub 2017 Aug 26.

PMID:
28865325
21.

Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naïve extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901.

Morikawa N, Inoue A, Sugawara S, Maemondo M, Harada T, Harada M, Fujita Y, Katoh T, Yokouchi H, Watanabe H, Usui K, Suzuki T, Sakakibara-Konishi J, Nagai H, Kanbe M, Nukiwa T.

Lung Cancer. 2017 Sep;111:38-42. doi: 10.1016/j.lungcan.2017.06.016. Epub 2017 Jul 1.

PMID:
28838395
22.

Case series on the association between blood levels and side effects of afatinib maleate.

Sato J, Morikawa N, Chiba R, Nihei S, Moriguchi S, Saito H, Yamauchi K, Kudo K.

Cancer Chemother Pharmacol. 2017 Sep;80(3):545-553. doi: 10.1007/s00280-017-3378-6. Epub 2017 Jul 17.

PMID:
28718011
23.

A comprehensive intervention following the clinical pathway of eating and swallowing disorder in the elderly with dementia: historically controlled study.

Arahata M, Oura M, Tomiyama Y, Morikawa N, Fujii H, Minani S, Shimizu Y.

BMC Geriatr. 2017 Jul 14;17(1):146. doi: 10.1186/s12877-017-0531-3.

24.

Pharmacokinetics of piperacillin-tazobactam in plasma, peritoneal fluid and peritoneum of surgery patients, and dosing considerations based on site-specific pharmacodynamic target attainment.

Murao N, Ohge H, Ikawa K, Watadani Y, Uegami S, Shigemoto N, Shimada N, Yano R, Kajihara T, Uemura K, Murakami Y, Morikawa N, Sueda T.

Int J Antimicrob Agents. 2017 Sep;50(3):393-398. doi: 10.1016/j.ijantimicag.2017.03.025. Epub 2017 Jul 8.

PMID:
28694230
25.

Elevated Plasma Transforming Growth Factor β1 Levels Predict the Development of Hypertension in Normotensives: The 14-Year Follow-Up Study.

Nakao E, Adachi H, Enomoto M, Fukami A, Kumagai E, Nakamura S, Nohara Y, Kono S, Sakaue A, Morikawa N, Tsuru T, Fukumoto Y.

Am J Hypertens. 2017 Aug 1;30(8):808-814. doi: 10.1093/ajh/hpx053.

PMID:
28575138
26.

Tumor thickness and histological features as predictors of invasive foci within preoperatively diagnosed ductal carcinoma in situ.

Mori K, Takeda M, Kodama Y, Kiyokawa H, Yasojima H, Mizutani M, Otani Y, Morikawa N, Masuda N, Mano M.

Hum Pathol. 2017 Jun;64:145-155. doi: 10.1016/j.humpath.2017.04.004. Epub 2017 Apr 20.

PMID:
28434924
27.

Pharmacokinetics and outcome of tazobactam/piperacillin in Japanese patients undergoing low-flow continuous renal replacement therapy: dosage considerations.

Kohama H, Ide T, Ikawa K, Morikawa N, Nishi S.

Clin Pharmacol. 2017 Feb 24;9:39-44. doi: 10.2147/CPAA.S127502. eCollection 2017.

28.

A Useful Tool As a Medical Checkup in a General Population-Bioelectrical Impedance Analysis.

Enomoto M, Adachi H, Fukami A, Kumagai E, Nakamura S, Nohara Y, Kono S, Nakao E, Morikawa N, Tsuru T, Sakaue A, Fukumoto Y.

Front Cardiovasc Med. 2017 Feb 2;4:3. doi: 10.3389/fcvm.2017.00003. eCollection 2017.

29.

Trends in coronary risk factors and electrocardiogram findings from 1977 to 2009 with 10-year mortality in Japanese elderly males - The Tanushimaru Study.

Nakamura S, Adachi H, Enomoto M, Fukami A, Kumagai E, Nohara Y, Kono S, Nakao E, Sakaue A, Tsuru T, Morikawa N, Fukumoto Y.

J Cardiol. 2017 Oct;70(4):353-358. doi: 10.1016/j.jjcc.2016.12.004. Epub 2017 Jan 18.

30.

Clinical pharmacokinetics of oral levofloxacin and sitafloxacin in epididymal tissue.

Sadahira T, Wada K, Ikawa K, Morikawa N, Kurahashi H, Yoshioka T, Ariyoshi Y, Kobayashi Y, Araki M, Ishii A, Watanabe M, Uehara S, Watanabe T, Nasu Y.

J Infect Chemother. 2017 Apr;23(4):214-217. doi: 10.1016/j.jiac.2016.12.010. Epub 2017 Jan 11.

PMID:
28089362
31.

Pulmonary Tumor Thrombotic Microangiopathy Caused by a Parotid Tumor: Early Antemortem Diagnosis and Long-term Survival.

Toyonaga H, Tsuchiya M, Sakaguchi C, Ajimizu H, Nakanishi Y, Nishiyama S, Morikawa N, Hayashi Y, Nagasaka Y, Yasui H.

Intern Med. 2017;56(1):67-71. doi: 10.2169/internalmedicine.56.7439. Epub 2017 Jan 1.

32.

Augmentation index (AI) in a dose-response relationship with smoking habits in males: The Tanushimaru study.

Tsuru T, Adachi H, Enomoto M, Fukami A, Kumagai E, Nakamura S, Nohara Y, Kono S, Nakao E, Sakaue A, Morikawa N, Fukumoto Y.

Medicine (Baltimore). 2016 Dec;95(51):e5368. doi: 10.1097/MD.0000000000005368.

33.

High non-relapse mortality and low relapse incidence in gender-mismatched allogeneic hematopoietic stem cell transplantation from a parous female donor with a male child.

Shinohara A, Inamoto Y, Kurosawa S, Hiramoto N, Ueda R, Tanaka T, Tada K, Kobayashi Y, Morikawa N, Okinaka K, Kim SW, Tajima K, Fukuda T.

Leuk Lymphoma. 2017 Mar;58(3):578-585. doi: 10.1080/10428194.2016.1205743. Epub 2016 Nov 28.

PMID:
27892749
34.

Serum Albumin and Cerebro-cardiovascular Mortality During a 15-year Study in a Community-based Cohort in Tanushimaru, a Cohort of the Seven Countries Study.

Umeki Y, Adachi H, Enomoto M, Fukami A, Nakamura S, Nohara Y, Nakao E, Sakaue A, Tsuru T, Morikawa N, Fukumoto Y.

Intern Med. 2016;55(20):2917-2925. Epub 2016 Oct 15.

35.

Severe drug eruptions due to lamotrigine in Japan based on data from the relief system of the Pharmaceuticals and Medical Devices Agency.

Saeki H, Yamada K, Morikawa N, Asahina A, Ochiai T, Iijima M.

Allergol Int. 2017 Jan;66(1):156-158. doi: 10.1016/j.alit.2016.07.006. Epub 2016 Aug 28. No abstract available.

36.

Pharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infections.

Matsumoto K, Watanabe E, Kanazawa N, Fukamizu T, Shigemi A, Yokoyama Y, Ikawa K, Morikawa N, Takeda Y.

Clin Pharmacol. 2016 Mar 30;8:15-8. doi: 10.2147/CPAA.S96143. eCollection 2016.

37.

Analysis of a single-codon E746 deletion in exon 19 of the epidermal growth factor receptor.

Ogasawara M, Nakamura Y, Morikawa N, Nitanai H, Moriguchi S, Chiba R, Saito H, Ohta M, Tanita T, Sugai T, Maeyama K, Yamauchi K, Takaoka Y.

Cancer Chemother Pharmacol. 2016 May;77(5):1019-29. doi: 10.1007/s00280-016-3021-y. Epub 2016 Apr 4.

PMID:
27042857
38.

The pharmacokinetics of ampicillin-sulbactam in anuric patients: dosing optimization for prophylaxis during cardiovascular surgery.

Yokoyama Y, Matsumoto K, Ikawa K, Watanabe E, Yamamoto H, Imoto Y, Morikawa N, Takeda Y.

Int J Clin Pharm. 2016 Aug;38(4):771-5. doi: 10.1007/s11096-016-0286-5. Epub 2016 Mar 21.

PMID:
27001408
39.

Feasibility study of short hydration using oral rehydration solution in cisplatin including chemotherapy of lung cancer.

Sato J, Morikawa N, Nitanai H, Nagashima H, Nihei S, Yamauti K, Kudo K.

J Pharm Health Care Sci. 2016 Mar 5;2:6. doi: 10.1186/s40780-016-0041-z. eCollection 2016.

40.

Pharmacokinetics of Prophylactic Ampicillin-Sulbactam and Dosing Optimization in Patients Undergoing Cardiovascular Surgery with Cardiopulmonary Bypass.

Yokoyama Y, Matsumoto K, Ikawa K, Watanabe E, Yamamoto H, Imoto Y, Morikawa N, Takeda Y.

Biol Pharm Bull. 2015;38(11):1817-21. doi: 10.1248/bpb.b15-00334.

41.

Therapeutic drug monitoring of voriconazole in Japanese patients: analysis based on clinical practice data.

Matsumoto K, Abematsu K, Shigemi A, Kanazawa N, Watanabe E, Yokoyama Y, Ikawa K, Morikawa N, Takeda Y.

J Chemother. 2016 Jun;28(3):198-202. doi: 10.1179/1973947815Y.0000000057. Epub 2016 May 27.

PMID:
26187373
42.

Pharmacokinetics and skin-tissue penetration of daptomycin in rats.

Matsumoto K, Kitaoka M, Kuroda Y, Ikawa K, Morikawa N, Sasaki J, Iketani O, Iwata S, Horino T, Hori S, Kizu J.

Clin Pharmacol. 2015 May 21;7:79-82. doi: 10.2147/CPAA.S83447. eCollection 2015.

43.

Penetration of piperacillin-tazobactam into human prostate tissue and dosing considerations for prostatitis based on site-specific pharmacokinetics and pharmacodynamics.

Kobayashi I, Ikawa K, Nakamura K, Nishikawa G, Kajikawa K, Yoshizawa T, Watanabe M, Kato Y, Zennami K, Kanao K, Tobiume M, Yamada Y, Mitsui K, Narushima M, Morikawa N, Sumitomo M.

J Infect Chemother. 2015 Aug;21(8):575-80. doi: 10.1016/j.jiac.2015.04.015. Epub 2015 May 14.

PMID:
26050020
44.

Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702.

Inoue A, Sugawara S, Maemondo M, Mori Y, Oizumi S, Harada M, Taima K, Morikawa N, Ishida T, Kinoshita I, Watanabe H, Suzuki T, Nakagawa T, Saito R, Nukiwa T.

Lung Cancer. 2015 Jul;89(1):61-5. doi: 10.1016/j.lungcan.2015.04.012. Epub 2015 May 4.

PMID:
26004087
45.

Characteristics and outcomes of patients diagnosed with norovirus gastroenteritis after allogeneic hematopoietic stem cell transplantation based on immunochromatography.

Ueda R, Fuji S, Mori S, Hiramoto N, Hashimoto H, Tanaka T, Tada K, Kobayashi Y, Morikawa N, Shinohara A, Okinaka K, Maeshima AM, Kurosawa S, Kim SW, Yamashita T, Fukuda T.

Int J Hematol. 2015 Jul;102(1):121-8. doi: 10.1007/s12185-015-1804-2. Epub 2015 May 1.

PMID:
25930664
46.

Pharmacokinetics and dosing estimation of meropenem in Japanese patients receiving continuous venovenous hemodialysis.

Kawano S, Matsumoto K, Hara R, Kuroda Y, Ikawa K, Morikawa N, Horino T, Hori S, Kizu J.

J Infect Chemother. 2015 Jun;21(6):476-8. doi: 10.1016/j.jiac.2015.02.011. Epub 2015 Mar 6.

PMID:
25869915
47.

[Folate antagonist].

Morikawa N.

Nihon Rinsho. 2015 Feb;73 Suppl 2:146-8. Japanese. No abstract available.

PMID:
25831740
48.

Evaluation of a pharmacokineticpharmacodynamic approach using software to optimize the carbapenem antibiotic regimen.

Ishihara N, Nishimura N, Tamaki H, Karino F, Miura K, Isobe T, Ikawa K, Morikawa N, Naora K.

Int J Clin Pharmacol Ther. 2015 Jun;53(6):422-9. doi: 10.5414/CP202191.

PMID:
25828635
49.

Risk factors for ganciclovir-induced thrombocytopenia and leukopenia.

Matsumoto K, Shigemi A, Ikawa K, Kanazawa N, Fujisaki Y, Morikawa N, Takeda Y.

Biol Pharm Bull. 2015;38(2):235-8. doi: 10.1248/bpb.b14-00588.

50.

[Health assessment of local residents who made full use of symptomatology skills and test device].

Akagawa S, Morikawa N, Ikeda K, Okazaki T, Takahashi S.

Yakugaku Zasshi. 2015;135(2):175-9. doi: 10.1248/yakushi.14-00201-3. Review. Japanese.

Supplemental Content

Loading ...
Support Center